Genetic Effects on Age-Dependent Onset and Islet Cell Autoantibody Markers in Type 1 Diabetes


Age-dependent associations between type 1 diabetes risk genes HLA, INS VNTR, and CTLA-4 and autoantibodies to GAD65 (GADAs), ICA512/IA-2, insulin, and islet cells were determined by logistic regression analysis in 971 incident patients with type 1 diabetes and 702 control subjects aged 0–34 years. GADAs were associated with HLA-DQ2 in young but not in older patients (P = 0.009). Autoantibodies to insulin were negatively associated with age (P < 0.0001) but positively associated with DQ8 (P = 0.03) and with INS VNTR (P = 0.04), supporting possible immune tolerance induction. ICA512/IA-2 were negatively associated with age (P < 0.0001) and with DQ2 (P < 0.0001) but positively associated with DQ8 (P = 0.04). Males were more likely than females to be negative for GADA (P < 0.0001), autoantibodies to islet cells (P = 0.04), and all four autoantibody markers (P = 0.004). The CTLA-4 3′ end microsatellite marker was not associated with any of the autoantibodies. We conclude that age and genetic factors such as HLA-DQ and INS VNTR need to be combined with islet autoantibody markers when evaluating the risk for type 1 diabetes development. Diabetes 51:1346–1355, 2002

The incidence of type 1 diabetes varies both by age and by sex, with males predominant in postpubertal young adults (1,2). Such age- and sex-dependent variation may in part be determined by markers for islet autoimmunity, such as autoantibodies to insulin (IAAs), GAD65 (GADAs), and ICA512/IA-2 (IA-2As) and their associations with age, sex, and genetic factors such as HLA (rev. in 3,4), the insulin gene on chromosome 11 (5,6), and the CTLA-4 gene on chromosome 2 (7,8). Previous studies have established that the frequency of immune markers, such as IAAs, GADAs, and IA-2As, at clinical onset varies with age (9,10). Autoantibodies to the ICA512/IA-2 autoantigen (11,12) are associated with HLA-DQ8 in patients (13) and are of particular interest because they may better predict type 1 diabetes in first-degree relatives (14,15). IAAs, widely known to be markedly affected by age at clinical onset (10,16), have been reported to be associated with HLA-DQ8, but only in patients who are younger than 10 years (9). Studies that combine incident children and young adults with type 1 diabetes are therefore needed to test the effects of genetic factors on autoantibody markers of β-cell autoimmunity and to dissect the age-dependent risk of type 1 diabetes. Association studies with a large number of incident patients can be a useful complement to genetic linkage studies (17).

The aim of the present investigation was to analyze the change in prevalence of IAAs, GADAs, IA-2As, and islet cell autoantibodies (ICAs) with age at clinical onset according to sex and genetic factors in patients aged 0–34 years. All available incident patients with type 1 diabetes diagnosed at 0–34 years of age (18) were therefore typed for HLA-DQ and for polymorphic genetic markers (INS VNTR) next to the insulin gene (IDDM2) on chromosome 11 (6,19) and for the 3′ end noncoding region AT repeat within the gene for CTLA-4 (IDDM12) on chromosome 2 (7,8). One means of controlling for the effects of potential confounding variables is to stratify the incident patient population on the basis of combinations of levels of these variables. However, the number of possible variables leads to a large number of strata in the data, making a conventional analysis based on contingency tables unwieldy. In addition, age at clinical onset takes on a wide range of values from 0 to 34 years, and so loss of information is expected from grouping ages into discrete categories, as is typically done in a contingency table analysis. To control simultaneously for confounding variables and to avoid loss of information from discretizing age at clinical onset, we used a logistic regression analysis (e.g., Breslow and Day [20]). Multiple logistic regression analysis permits efficient...
TABLE 1
Number (%) of incident patients with type 1 diabetes and control subjects in relation to age, sex, and geographic location

<table>
<thead>
<tr>
<th>Geographical Distribution (north to south)</th>
<th>Patients</th>
<th>Control Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Umeå</td>
<td>102 (14.5)</td>
<td>123 (17.7)</td>
</tr>
<tr>
<td>Uppsala</td>
<td>152 (21.7)</td>
<td>197 (20.3)</td>
</tr>
<tr>
<td>Stockholm</td>
<td>165 (15.0)</td>
<td>203 (20.9)</td>
</tr>
<tr>
<td>Linköping</td>
<td>118 (16.8)</td>
<td>138 (14.2)</td>
</tr>
<tr>
<td>Göteborg</td>
<td>129 (18.4)</td>
<td>186 (19.2)</td>
</tr>
<tr>
<td>Lund</td>
<td>96 (13.7)</td>
<td>124 (12.8)</td>
</tr>
</tbody>
</table>

The distributions of age, sex, and regional geographic difference between patients and control subjects, according to χ² tests on 4 (P < 0.0001), 1 (P = 0.004), and 5 (P = 0.04) degrees of freedom, respectively.

RESEARCH DESIGN AND METHODS

Subjects. The two population-based matched case-control studies merged in the present study have been described elsewhere (18). Patients received diagnoses and classifications according to the World Health Organization (WHO) criteria. In the first study, all incident patients with type 1 diabetes who were younger than 15 years and received a diagnosis anywhere in Sweden between 1 September 1986 and 31 December 1987 were asked to participate. Matched control subjects were selected as described (21). The second study comprised incident patients with diabetes who were aged 15–34 years and received their diagnosis anywhere in Sweden between 1 January 1987 and 31 December 1988; matched control subjects were also ascertained (10). The two studies administered overlapping years were combined for a total of 971 incident patients with type 1 diabetes and 702 control subjects. The distributions of age, sex, and place of residence for incident patients with type 1 diabetes and control subjects are summarized in Table 1.

Genetic markers

HLA (IDDM1). HLA typing of DQA1 and DQB1 was carried out by PCR amplification of the second exon of the genes followed by dot blot hybridization of sequence-specific oligo probes and by restriction fragment–length polymorphism using DR- and DQ-based probes to establish haplotypes (22,23). HLA-BQ genotypes were available on 832 of the 971 patients (85.7%) and 618 of the 702 control subjects (88.0%).

Insulin gene VNTR (IDDM2). Whole genomic DNA (25 ng) was amplified with primers flanking the polymorphic HphI site in the insulin gene upstream sequence, as described (6). The presence or absence of the HphI site (–23) is linked to the upstream variable number of tandem repeats (VNTR) flanking the insulin gene (INS). The PCR product of 50 cycles was digested at 37°C overnight with HphI and separated by agarose gel electrophoresis in parallel with a 100-bp ladder, which were already genotyped individuals were included as control subjects (6). The gels were photographed, and the banding patterns of samples were scored independently by two investigators as either class I (short VNTR or lower band) or class II (long VNTR or upper band) alleles (5). No class II alleles were present in these Swedish white patients. INS VNTR genotypes were available on 728 of the 971 (75.1%) patients and 522 of the 702 (74.8%) control subjects (Table 2).

CTLA-4 microsatellite (IDDM12). The CTLA-4 3′ end microsatellite was typed using two standard methods of PCR and PAGE. In the first assay,描述在详细地elsewhere (8), oligonucleotides with sequences flanking the 5′ UTR region containing the AT repeats were used as primers in a PCR to amplify selectively the polymorphic region. The first assay was used to genotype 616 patients and 500 control subjects for CTLA-4. In the second assay, we used a high-throughput genotyping method with infrared dyes (IRDs) at two wavelengths to label PCR products. DNA was dispensed into 96-well plates using a Hydra robot and vacuum-dried before the PCR mixture was added and the samples cycled (35 times at 94°C for 15 s, 50–58°C for 15 s, and 72°C for 15 s) using a Peltier Thermal Cycler (MJ Research). Each reaction contained 50 ng of DNA, primers (0.2 μmol/l each), 50 μmol/l KCl, 10 mmol/l Tris, 1–2.5 mmol/l MgCl₂, 0.5 units of Taq polymerase, and 0.15–0.70 μmol/l IRD label. Products were labeled during strand synthesis with the incorporation of the IRD-labeled d4TP. A LI-COR 4200 sequencing machine was used for electrophoresis. Samples were loaded with a multichannel pipette onto 18-cm 6% polyacrylamide gels; after electrophoresis, the gel image was analyzed by the genotyping software (SAGA) that was used to call alleles at a sizing accuracy of 0.2 bp. The CTLA-4 alleles of the 135 patients were calibrated to the first assay using a regression equation based on 94 control subjects with complete genotypes from both assays. Parameter estimates for the calibration equation were robust to outsourcing assay measurements (24). The resulting prediction equation was used to impute missing alleles for the first assay based on the LI-COR genotypes from the second assay. All alleles with resulting relative length longer than 1.0 (10 AT repeats) were classified as long (L), whereas alleles with relative length of 1.0 or shorter were classified as short (S). The classification was based on the relative allele length distribution of control subjects shown in Fig. 1; for comparison, the distribution of patients is also shown. CTLA-4 genotypes were available on 751 of the 971 patients (96.5%) and 502 of the 702 control subjects (71.5%)

TABLE 2
Distribution of INS VNTR genotypes in incident patients with type 1 diabetes and control subjects aged 0–34 years

<table>
<thead>
<tr>
<th>Number (%) of INS VNTR genotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>I/I</td>
</tr>
<tr>
<td>III/I</td>
</tr>
<tr>
<td>III/III</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

Patients

<table>
<thead>
<tr>
<th>Number (%) of INS VNTR genotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>I/I</td>
</tr>
<tr>
<td>III/I</td>
</tr>
<tr>
<td>III/III</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

The distribution of III/III, III/I, and I/I genotypes differs between patients and control subjects, according to χ² test on 2 degrees of freedom (P < 0.0001).

Immune markers

Insulin antibodies. Autoantibodies (IAAs) as well as antibodies to insulin were measured by radioassay using acid-extracted cold insulin and insulin displacement as described (25–27). IAAs percent measurements were available on 929 of the 971 (95.7%) patients and 668 of the 702 control subjects (95.2%). However, in 201 patients with IAA measurements, sera were sampled >3 weeks after beginning insulin therapy, precluding reliable IAA testing (10). These patients were therefore excluded from the analysis of IAA.

Glutamate decarboxylase autoantibodies. Antibodies to radiolabeled human Mr 65,000 glutamate decarboxylase (GADA) were quantified by fluid-phase immunoprecipitation assay using fluorographic densitometry as described (13,28) except that for 15 to 35-year-olds, GADA5 were radiolabeled by coupled in vitro transcription and translation, as described (29,30). The two assay formats correlate well, and autoantibody levels are expressed as GADA index as described elsewhere (29), using the WHO–Juvenile Diabetes Foundation (WJDF) standard (31) as the positive control. GADA index measurements were available on 938 of the 971 patients (96.0%) and 682 of the 702 control subjects (97.2%)

Ilet antigen-2 or ICA512 autoantibodies. Antibodies to ICA512/Ia-2 (ICA512) (12,32) were measured by radiobinding immunoassay (33). The 3′ portion of the ICA512cDNA (32) corresponding to the cytoplasmic portion of the protein (residues 602–709) was amplified by RT–PCR from human HTB-14 glioblastoma cells (12). After expression in DHU1B Escherichia coli, sequenced plasmid DNA was identical to Genbank sequence L18983. In vitro translation with [35S]-methionine (29) yielded a 46-kDa polypeptide highly precipitable by diabetes sera. Radiobinding assays used scintillation counting of protein A-Sepharose pellets, and autoantibody levels are expressed as an ICA512/Ia-Ia index as described (29), using the WJDF standard as a positive control (31). ICA512/Ia-Ia index measurements were available on 907 of the 971 patients (95.6%) and 671 of the 702 control subjects (95.6%).

Ilet cell (cytoplasmic) antibodies. Ilet cell cytoplasmic antibodies (ICAs) were measured by indirect two-color immunofluorescence using blood group O frozen human pancreas as described (34). The same pancreas was used throughout the study. Coded slides were evaluated by two independent
observers. Samples were titered in doubling dilutions to determine end points for conversion to JDF units (35) as described (34). ICA measurements of 0 JDF units corresponded to no detectable antibody. ICA JDF unit measurements were available on 969 of the 971 patients (99.8%) and 700 of the 702 control subjects (99.7%).

Statistical methods

Antibody status. For IAA, GADA, ICA512/IA-2A, and ICA, the smallest and largest measurements differed by at least an order of magnitude, both in patients and control subjects. To normalize values and bring them onto a comparable scale, antibody measurements were shifted and then transformed by taking the natural logarithm (36). For each antibody population in both patients and control subjects, a mixture of at least two distributions was expected, corresponding to a subpopulation of antibody-negative individuals and at least one subpopulation of antibody-positive individuals. This was confirmed by plotting the ordered transformed antibody measurements against the quantiles of a standard normal distribution in both patients and control subjects. Such quantile-quantile plots are expected to show data from a single normally distributed subpopulation falling along a straight line, with slope equal to the standard deviation of the distribution (36). Data from multiple normally distributed subpopulations with different means are expected to fall along different lines. Cutoffs for declaring antibody positivity are indicated in the original scale of measurement and are IAA Δ percent >0.80, GADA index >0.07, ICA512/IA-2A index >0.05, and ICA JDF units >0.

In this large cohort of 971 patients, 42 of 882 (5%) with complete data on all antibodies were ICA-positive but negative for IAA, GADA, and ICA512/IA-2A. Hence, ICA are also analyzed.

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Distribution of CTLA-4 genotypes in incident patients with type 1 diabetes and control subjects aged 0–34 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (%) of CTLA-4 genotypes</td>
<td>L/L</td>
</tr>
<tr>
<td>Control subjects</td>
<td>71 (14.1)</td>
</tr>
<tr>
<td>Patients</td>
<td>89 (11.9)</td>
</tr>
</tbody>
</table>

The distribution of S/S, S/L, and L/L genotypes differs between patients and control subjects, according to a χ² test on 2 degrees of freedom (P = 0.002).
which is referred to as logit (\(\log\)!

Logistic regression models the natural logarithm of the odds, or the log odds,

antibody are therefore 2.7

interpreted by holding

dependence, we avoided discretization of age at onset. Let

hypotheses regarding speci-

We stress that the purpose of these summary tables is descriptive rather than

summary tables. Selected summary tables report the proportion of individuals

patients homozygous for these alleles or haplotypes, who were otherwise

for the CTLA-4 long allele, the class I INS VNTR allele, or DQ2, DQ8, or DQ6.2

All of the above and

results in Table 5

support numerous observations that IAAs are more common

likely ratio tests from the logistic regression analysis confirms the negative association between IAA and

age at onset (\(P < 0.0001\)) and the positive associations between IAA and DQ8 (\(P = 0.03\)) and IAA and the class I

alleles of INS VNTR (\(P = 0.04\)). Fitted IAA prevalences are

positive for DQA7 and DQ8-negative patients: 27% of patients with no DQ8 haplotypes (95% CI 20–34), 41% of patients with one DQ8 haplotype (35–46), and 42% of patients with two DQ8 haplotypes (26–57) were positive for IAA. Finally, the unadjusted frequencies in Table 5

from the logistic regression analysis allows comparison of patients in subgroups defined by different levels of an

exploratory descriptive analysis based on unadjusted fre-

frequencies from contingency tables, and then results of hypothesis tests (i.e., \(P\) values) are presented from a logistic regression analysis that adjusts for confounding variables.

IAA. In the exploratory analysis, the unadjusted frequency of IAA increased with the number of class I alleles of INS VNTR: 15% of III/III patients (95% CI 0–30), 30% of I/III patients (22–38), and 40% of I/I patients (35–45) were positive for IAA. Unadjusted frequencies of IAA were higher in DQ8-positive than in DQ8-negative patients: 27% of patients with no DQ8 haplotypes (95% CI 20–34), 41% of patients with one DQ8 haplotype (35–46), and 42% of patients with two DQ8 haplotypes (26–57) were positive for IAA. Finally, the unadjusted frequencies in Table 5

were used to calculate fitted antibody prevalences, odds ratios, and approximate 95% CIs. The

in the baseline group composed of female patients aged 16.5

years, who carry genotypes X/X at HLA-DQ, S/S at CTLA-4, and III/III at INS

VNTR, where DQX is any HLA-DQ haplotype other than DQ2, DQ8, or DQ6.2.

Backward elimination (e.g., Weisberg [36]) of sex and genetic markers was used to simplify the initial model. When possible, the modeled antibody response in age was then reduced to a simple linear or quadratic function. All model reductions were based on likelihood ratio tests (e.g., Breslow and Day [30]) with significance level 10% or more for exclusion of variables. A relatively liberal significance level was chosen to yield an expanded set of possible exploratory variables for a second phase of model building. In the second model-building stage, terms were added to quantify two-way interactions between remaining explanatory variables and departures from a multiplicative model in the number of alleles or haplotypes for genetic factors. Terms were added by forward selection (e.g., Weisberg [36]) with significance level \(\leq 5\%\) for inclusion. Higher-order interactions were fit and tested only in the presence of lower-order terms, with the exception of the interaction term for the potentially effect of DQ8 and DQ8 in DQ82 heterozygotes and the interaction term for DQ8 and age at clinical onset. The final model thus obtained was used to describe the change with age at onset in antibody prevalence among subsets of incident patients, with subsets defined by sex and by the genetic factors HLA, INS VNTR, and CTLA-4. Parameter estimates from the final model were used to calculate fitted antibody prevalences, odds ratios, and approximate 95% CIs.

RESULTS

In the following, the data are introduced by way of an exploratory descriptive analysis based on unadjusted frequencies from contingency tables, and then results of hypothesis tests (i.e., \(P\) values) are presented from a logistic regression analysis that adjusts for confounding variables.

IAA. In the exploratory analysis, the unadjusted frequency of IAA increased with the number of class I alleles of INS VNTR: 15% of III/III patients (95% CI 0–30), 30% of I/III patients (22–38), and 40% of I/I patients (35–45) were positive for IAA. Unadjusted frequencies of IAA were higher in DQ8-positive than in DQ8-negative patients: 27% of patients with no DQ8 haplotypes (95% CI 20–34), 41% of patients with one DQ8 haplotype (35–46), and 42% of patients with two DQ8 haplotypes (26–57) were positive for IAA. Finally, the unadjusted frequencies in Table 5

were used to calculate fitted antibody prevalences, odds ratios, and approximate 95% CIs. The

in the baseline group composed of female patients aged 16.5

years, who carry genotypes X/X at HLA-DQ, S/S at CTLA-4, and III/III at INS

VNTR, where DQX is any HLA-DQ haplotype other than DQ2, DQ8, or DQ6.2.

Backward elimination (e.g., Weisberg [36]) of sex and genetic markers was used to simplify the initial model. When possible, the modeled antibody response in age was then reduced to a simple linear or quadratic function. All model reductions were based on likelihood ratio tests (e.g., Breslow and Day [30]) with significance level 10% or more for exclusion of variables. A relatively liberal significance level was chosen to yield an expanded set of possible exploratory variables for a second phase of model building. In the second model-building stage, terms were added to quantify two-way interactions between remaining explanatory variables and departures from a multiplicative model in the number of alleles or haplotypes for genetic factors. Terms were added by forward selection (e.g., Weisberg [36]) with significance level \(\leq 5\%\) for inclusion. Higher-order interactions were fit and tested only in the presence of lower-order terms, with the exception of the interaction term for the potentially effect of DQ8 and DQ8 in DQ82 heterozygotes and the interaction term for DQ8 and age at clinical onset. The final model thus obtained was used to describe the change with age at onset in antibody prevalence among subsets of incident patients, with subsets defined by sex and by the genetic factors HLA, INS VNTR, and CTLA-4. Parameter estimates from the final model were used to calculate fitted antibody prevalences, odds ratios, and approximate 95% CIs.

RESULTS

In the following, the data are introduced by way of an exploratory descriptive analysis based on unadjusted frequencies from contingency tables, and then results of hypothesis tests (i.e., \(P\) values) are presented from a logistic regression analysis that adjusts for confounding variables.

IAA. In the exploratory analysis, the unadjusted frequency of IAA increased with the number of class I alleles of INS VNTR: 15% of III/III patients (95% CI 0–30), 30% of I/III patients (22–38), and 40% of I/I patients (35–45) were positive for IAA. Unadjusted frequencies of IAA were higher in DQ8-positive than in DQ8-negative patients: 27% of patients with no DQ8 haplotypes (95% CI 20–34), 41% of patients with one DQ8 haplotype (35–46), and 42% of patients with two DQ8 haplotypes (26–57) were positive for IAA. Finally, the unadjusted frequencies in Table 5

were used to calculate fitted antibody prevalences, odds ratios, and approximate 95% CIs. The

in the baseline group composed of female patients aged 16.5
TABLE 5
Proportion (95% CI) of incident patients with type 1 diabetes who are antibody positive by age category

<table>
<thead>
<tr>
<th>Age at clinical onset (years)</th>
<th>0–6</th>
<th>7–13</th>
<th>14–20</th>
<th>21–27</th>
<th>28–34</th>
</tr>
</thead>
<tbody>
<tr>
<td>IAA</td>
<td>0.69 (0.60–0.79)</td>
<td>0.41 (0.34–0.48)</td>
<td>0.24 (0.15–0.032)</td>
<td>0.19 (0.10–0.29)</td>
<td>0.13 (0.06–0.22)</td>
</tr>
<tr>
<td>GADA by number of DQ2 haplotypes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0.28 (0.14–0.42)</td>
<td>0.44 (0.35–0.52)</td>
<td>0.42 (0.30–0.55)</td>
<td>0.62 (0.47–0.74)</td>
<td>0.63 (0.49–0.76)</td>
</tr>
<tr>
<td>1</td>
<td>0.51 (0.39–0.63)</td>
<td>0.63 (0.54–0.72)</td>
<td>0.61 (0.49–0.73)</td>
<td>0.69 (0.56–0.81)</td>
<td>0.66 (0.48–0.83)</td>
</tr>
<tr>
<td>2</td>
<td>0.75 (0.25–1.00)</td>
<td>0.75 (0.25–1.00)</td>
<td>0.80 (0.67–1.00)</td>
<td>0.62 (0.25–0.88)</td>
<td>0.25 (0.00–0.75)</td>
</tr>
<tr>
<td>ICA512/IA-2A</td>
<td>0.68 (0.59–0.77)</td>
<td>0.72 (0.67–0.78)</td>
<td>0.56 (0.47–0.64)</td>
<td>0.40 (0.31–0.50)</td>
<td>0.30 (0.21–0.40)</td>
</tr>
<tr>
<td>ICA</td>
<td>0.89 (0.83–0.95)</td>
<td>0.85 (0.81–0.90)</td>
<td>0.77 (0.70–0.84)</td>
<td>0.68 (0.59–0.77)</td>
<td>0.67 (0.57–0.77)</td>
</tr>
</tbody>
</table>

The purpose of the table is descriptive rather than inferential, and so no P values are reported. Statistical testing of hypotheses is deferred to the logistic regression analysis. Of the original 971 patients, 491 (51.0%), 652 (67.1%), 651 (67.0%), and 669 (68.9%) were analyzed for IAA, GADA, ICA512/IA-2A, and ICA, respectively (see Table 4).

GADA. In the exploratory analysis, the unadjusted frequency of GADA was higher in female (69%; 95% CI 63–74) than in male subjects (45%; 40–50). The unadjusted frequencies in Table 5 suggest that the prevalence of GADA increases with the number of DQ2 haplotypes in younger age groups but not necessarily in older age groups and that GADA are more common in older- than in younger-onset patients. Likelihood ratio tests from the logistic regression analysis confirmed the positive association between GADA and age at onset (P = 0.001) and between GADA and sex (P < 0.0001). DQ2 was positively associated with GADA (P < 0.0001), but a statistically significant attenuation of its effect was observed with age at onset (P = 0.009). Fitted GADA prevalences are shown plotted against age at onset in Fig. 4, by number of DQ2 haplotypes in female (Fig. 4A) and male (Fig. 4B) patients.

After the observed effects of age at clinical onset and DQ2 were adjusted for, the odds of GADA for female patients were estimated to be 3.1 times those for male patients (95% CI 2.2–4.3). By contrast, in patients with age at clinical onset at 34 years, the odds of GADA did not differ significantly according to the number of DQ2 haplotypes (P = 0.55). After other variables were adjusted for, there was insufficient statistical evidence for an interaction between DQ8 and age at clinical onset (P = 0.08) and for a potentiating effect of DQ2 and DQ8 on the odds of GADA in DQ2/8 heterozygotes (P = 0.12).

ICA512/IA-2A. In the exploratory analysis, the unadjusted frequency of ICA512/IA-2A decreased with increasing age at onset (Table 5). Unadjusted ICA512/IA-2A frequencies decreased with the number of DQ2 haplotypes and increased with the number of DQ8 haplotypes (Table 6). ICA512/IA-2A seemed to be slightly more common in male (59%; 95% CI 54–63) than in female subjects (55%; 49–61). Likelihood ratio tests from the logistic regression

FIG. 3. Fitted prevalences of IAA against age at onset, by number of DQ8 haplotypes (P = 0.03) in incident patients with type 1 diabetes negative for the INS VNTR class I allele (A), and by number of INS VNTR class I alleles (P = 0.04) in incident patients with type 1 diabetes negative for the DQ8 haplotype (B).

FIG. 4. Fitted prevalences of GADA against age at onset, by number of DQ2 haplotypes (P < 0.0001) in female (A) and male (B) incident patients with type 1 diabetes. Female patients had a significantly higher prevalence of GADA than males (P < 0.0001), irrespective of the number of DQ2 haplotypes or of the age at clinical onset. The positive association between GADA and DQ2 in younger patients is attenuated with age at onset (P = 0.009). In patients with two DQ2 haplotypes, the apparent decrease with age at onset in the prevalence of GADA is not statistically significant (P = 0.32).
analysis confirmed the negative associations between ICA512/IA-2A and age at onset \((P < 0.0001)\) and ICA512/IA-2A and DQ8 \((P < 0.0001)\), as well as the positive association between ICA512/IA-2A and DQ8 \((P = 0.04)\). A statistically marginal association was observed between ICA512/IA-2A and sex \((P = 0.06)\). Fitted ICA512/IA-2A prevalences are shown in Fig. 5, plotted against age at onset by number of DQ2 haplotypes in female (Fig. 5A) and male (Fig. 5B) patients negative for DQ8 and by number of DQ8 haplotypes in female (Fig. 5C) and male (Fig. 5D) patients negative for DQ2.

After the observed effects of DQ2, DQ8, and age at clinical onset were controlled for, the odds of ICA512/IA-2A for male subjects were estimated to be 1.4 times those for female subjects \((95\% \text{ CI } 0.97–1.9)\). The odds of ICA512/IA-2A were estimated to increase by a factor of 1.4 (1.0–1.8) with each additional DQ8 haplotype and to decrease by a factor of 0.52 (0.38–0.70) with each additional DQ2 haplotype. For patients carrying two DQ8 haplotypes, the odds of ICA512/IA-2A were estimated to be 1.8 times those for patients carrying no DQ8 haplotypes (1.0–3.3). For patients carrying two DQ2 haplotypes, the odds of ICA512/IA-2A were estimated to be 0.27 those for patients carrying no DQ2 haplotypes (0.15–49). The observed negative association between ICA512/IA-2A and DQ8 cannot be attributed to exclusion of DQ8 because the effect of DQ8 is adjusted for by the logistic regression.

ICA. In the exploratory analysis, the unadjusted frequency of ICA was higher in female \((84\% ; 79–88)\) than in male patients \((76\% ; 71–80)\) and higher in patients carrying two DQ8 haplotypes \((80\% ; 69–89)\) or a single DQ8 haplotype \((83\% ; 79–86)\) than in patients carrying no DQ8 haplotypes \((72\% ; 66–78)\). ICA seemed to be more common in patients carrying the class I allele of INS VNTR than in patients not carrying this allele: 68% of patients with no class I alleles \((48–74)\), 75% of patients with one class I allele \((69–81)\), and 81% of patients with two class I alleles \((77–84)\) were positive for ICA. The unadjusted frequency of ICA decreased with age at onset (Table 5).

Likelihood ratio tests from the logistic regression analysis confirmed the negative association between ICA and age at onset \((P < 0.0001)\) and the positive association between ICA and DQ8 \((P = 0.03)\). ICA and sex were also associated \((P = 0.04)\). A nonmultiplicative effect in the number of DQ8 haplotypes to increase the odds of ICA was not evident after adjusting for the observed effects of sex and age at clinical onset in the logistic regression \((P = 0.18)\). There was no apparent association between ICA and INS VNTR after adjusting for other variables \((P = 0.12)\). Fitted ICA prevalences are shown in Fig. 6, plotted against age at onset by number of DQ8 haplotypes in female (Fig. 6A) and male (Fig. 6B) patients. In female patients, the estimated odds of ICA were 1.5 times those in male patients \((95\% \text{ CI } 1.0–2.3)\).

With each additional DQ8 haplotype, the odds of ICA were estimated to increase by a factor of 1.4 \((95\% \text{ CI } 1.0–2.0)\). In patients carrying two DQ8 haplotypes, the estimated odds of ICA were 2.1 \((\sim 1.4^2)\) times those in patients carrying no DQ8 haplotypes \((95\% \text{ CI } 1.1–4.0)\).

**Antibody-negative patients.** As age at clinical onset increased, so did the proportion of patients negative for all

![Fig. 5. Fitted prevalences of ICA512/IA-2A against age at onset by number of DQ2 haplotypes \((P < 0.0001)\) in female (A) and male (B) incident patients with type 1 diabetes negative for DQ8 and by number of DQ8 haplotypes \((P = 0.04)\) in female (C) and male (D) patients negative for DQ2. Male patients had a marginally significant increased prevalence of ICA512/IA-2A compared with female patients \((P = 0.06)\), irrespective of the number of DQ2 or DQ8 haplotypes or of the age at clinical onset.](image1)

![Fig. 6. Fitted prevalences of ICA against age at onset, by number of DQ8 haplotypes \((P = 0.03)\) in female (A) and male (B) incident patients with type 1 diabetes. Female patients had a significantly higher prevalence of ICA than male patients \((P = 0.04)\), irrespective of the number of DQ2 haplotypes or of the age at clinical onset.](image2)

**TABLE 6**

<table>
<thead>
<tr>
<th>Number of haplotypes</th>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>DQ2</td>
<td>0.65 (0.60–0.70)</td>
<td>0.52 (0.47–0.58)</td>
<td>0.24 (0.10–0.41)</td>
</tr>
<tr>
<td>DQ8</td>
<td>0.47 (0.40–0.54)</td>
<td>0.62 (0.57–0.66)</td>
<td>0.69 (0.56–0.80)</td>
</tr>
</tbody>
</table>

The purpose of the table is descriptive rather than inferential, and so no \(P\) values are reported. Statistical testing of hypotheses is deferred to the logistic regression analysis. Of the original 971 patients, 651 \((67.0\%)\) were analyzed for ICA512/IA-2A (see Table 4).
four of the IAA, GADA, ICA512/IA-2A, and ICA markers. Approximately 3% of patients aged 5 years at clinical onset versus 33% of patients aged 34 years at clinical onset were expected to be antibody-negative ($P < 0.0001$). Patients negative for all four antibody markers were mostly male (69%; 95% CI 59–78), and the conditional odds of being male given that an incident patient was negative for all four antibody markers were significantly higher than the overall odds of being male ($P = 0.004$), irrespective of age at clinical onset. The observed effect of sex was not modified by genetic factors, and genetic factors were not predictive.

**DISCUSSION**

Type 1 diabetes may occur at any age, but clinical symptoms, genetic factors, and immune phenomena vary with age at onset. To our knowledge, the present study is the first detailed analysis of age-specific associations between multiple genetic factors (HLA, INS, VNTR, and CTLA-4) and the four most commonly used autoantibody markers for type 1 diabetes. The validity of our investigation is underscored by the high ascertainment of incident patients and control subjects in the homogeneous Swedish population (18). As shown here, the data on matched control subjects and patients 0–34 years of age at clinical diagnosis (18) made it possible for us to investigate the effect of genetic factors on autoantibody markers of β-cell autoimmunity and therefore on age-dependent risk for type 1 diabetes. Taken together, our data permit a comprehensive analysis of how genetic factors are associated with autoantibody markers and contribute to the age-dependent risk of type 1 diabetes in 0- to 34-year-olds.

Our study confirms several previous findings of age dependence in immune markers among incident patients with type 1 diabetes (3). Older patients were more likely than younger patients to be negative for all four antibody markers. For example, 33% of patients aged 34 years at clinical onset were expected to be negative for all antibodies, compared with 3% of patients aged 5 years at clinical onset. Most patients who were negative for all four antibody markers were male (69%; 95% CI 59–78). The novel observation that more male than female subjects are negative for all four antibody markers may relate to the male preponderance of type 1 diabetes among young adults (1,2), particularly if the adult onset is less influenced by autoimmunity than the childhood onset form of type 1 diabetes.

Our observation that both GADAs and ICAs were more frequent in female subjects is consistent with other studies and supports the notion that autoimmunity is more common among females (for a review, see Schranz and Lernmark [3]). This is best illustrated by the estimated odds of GADA and ICA for female subjects, which were, respectively, 3.1 (95% CI 2.2–4.3) and 1.5 (95% CI 1.0–2.3) times those for male subjects. There was no evidence that the effects of any of the genetic factors were modified by sex for any of the immune markers. In contrast to the results for GADA and ICA, the estimated odds of ICA512/IA-2A for male subjects were 1.4 (95% CI 0.97–1.9) times those for female subjects. The marginally significant effect of sex on ICA512/IA-2A ($P = 0.06$) suggests that development of ICA512/IA-2A may signify a type 1 diabetes disease process that is more common in males. Additional studies are needed to determine to what extent, if any, a possible male ICA512/IA-2A preponderance may contribute to the increased incidence of type 1 diabetes among young adult males.

Our present analysis suggests that genetic factors influence antibody status. First, the association between DQ2 and GADA shown previously (14,39) is confirmed in this group of 0- to 34-year-old incident patients with type 1 diabetes. More important, however, is the observation that the positive association between GADA and DQ2 is attenuated with age at onset suggesting that early development of GADA may be closely controlled by DQ2, DR3, or both (22). Although DQ8 heterodimers are known to bind specific GAD65 peptides (40), it is possible that disease-associated peptide binding also takes place on DQ2 or perhaps DR3 heterodimers. Again, this risk is illustrated by the odds of GADA, which are estimated to increase by a factor of 3 (95% CI 2–4) with each additional DQ2 haplotype for patients aged 5 years at clinical onset. By contrast, the odds do not differ significantly according to DQ2 for patients aged 34 years at clinical onset ($P = 0.55$). For patients carrying two HLA-DQ2 haplotypes, support for the apparent decrease of GADA prevalence with age at onset is weak ($P = 0.32$). It cannot be excluded that in GADA-negative patients with two HLA-DQ2 haplotypes, GADAs have either already disappeared or, more plausible in the older patients, appear after clinical diagnosis (41). Conversely, patients carrying no or one DQ2 haplotype have increased frequencies of GADA with increasing age, consistent with the possibility that GAD65 peptide presentations necessary for a subsequent T-cell–dependent autoantibody response can also occur on HLA class II heterodimers other than DQ2. We conclude that although there is a highly significant association between GADA and DQ2 overall, the association between type 1 diabetes and DQ2 is much stronger in younger- than in older-onset patients.

Second, we confirm previous observations (42) that DQ8 is positively associated with IAA, ICA512/IA-2A, and ICA. If we speculate that HLA associations are related to antigen presentation of the HLA class II molecule, then the association between DQ8 and ICA is complicated because the ICA reaction is likely to represent numerous antigens. The possibility that the DQ8 class II molecule is important to the disease process is illustrated by the odds of IAA and ICA512/IA-2A, which are estimated to increase by a factor of 1.5 (95% CI 1.0–2.1) and 1.4 (1.0–1.8), respectively, for each additional DQ8 haplotype. DQ8 is of potential importance to both disease initiation and disease progression because the DQ 8/8 or 8/X genotype category, where “X” is any DQ haplotype other than DQ2, DQ8, or DQ6, was ranked behind DQ2/8 but ahead of the DQ 2/2 or 2/X genotype category in terms of risk for type 1 diabetes (18). In contrast to DQ2/8, the relative risk of type 1 diabetes associated with the DQ8/8 or 8/X genotype category was not affected by age at clinical onset (18). Therefore, DQ8 may be important to the development of IAA and ICA512/IA-2A, even though the frequencies of these two antibody markers decrease with age at clinical onset. It should be noted that DQ8 effects may be mediated through DQ8 itself...
or, especially in the case of ICA512/IA-2A, via the closely linked DR4 alleles (43).

Third, our novel observation of a negative association between DQ2 and ICA512/IA-2A is potentially important and may reflect the possibility that ICA512/IA-2 peptides are poorly presented by DQ2 class II molecules. Peptide binding analyses to DQ2 or peptide elution studies from homozygous DQ2 heterodimers will be important to test the possibility of reduced binding. The alternative hypothesis is that DQ2 is associated with profound binding and induction of immunologic tolerance that is not broken by an islet autoimmune process. The negative association seems to be multiplicative by the number of DQ2 haplotypes, with the estimated odds of ICA512/IA-2A decreasing by a factor of 0.52 (95% CI 0.38–0.70) for each DQ2 haplotype. The following illustration from our data suggests that the negative association between DQ2 and ICA512/IA-2A may be explained by the DQ2 molecules themselves. After adjusting for other variables, ICA512/IA-2A frequencies for patients carrying two DQ2 haplotypes were lower than frequencies for patients carrying no or one DQ2 haplotype. Specifically, coding as Y any HLA-DQ haplotype other than DQ2 or DQ8, the estimated odds of ICA512/IA-2A relative to those for DQY/Y patients of the same age were, in order from lowest to highest, 0.27 (95% CI 0.15–0.49), 0.52 (0.38–0.70), 0.70 (0.44–1.1), 1.3 (1.0–1.8), and 1.8 (1.0–3.3) for DQ2/2, 2/Y, 2/8, 8/Y, and 8/8 patients, respectively. We speculate, therefore, that ICA512/IA-2A affects diabetes risk primarily in non-DQ2 subjects. Because ICA512/IA-2A has been shown to predict type 1 diabetes, most likely as a marker of ongoing β-cell destruction, we speculate that this process may be decelerated in DQ2 individuals because of a reduced immune response to ICA512/IA-2. This speculation is consistent with the observation that DQ2-DR3 patients have higher C-peptide levels at the time of clinical diagnosis (44,45).

Fourth, our novel observation that IAA but not GADA and ICA512/IA-2A were associated with the (−23) polymorphism that is in linkage disequilibrium with INS VNTR alleles suggests that the contribution of the INS VNTR may be specific to insulin as an autoantigen. The suggestion is strengthened by the observation that with each additional class I allele, the odds of IAA were estimated to increase by a factor of 1.5 (95% CI 1.0–2.2). Our observation can therefore be taken as support for the hypothesis that the association between INS VNTR and type 1 diabetes is due to variable induction of immunologic tolerance to insulin because of differences in thymic insulin gene expression (46,47). However, these authors were unable to confirm the hypothesis, possibly owing to a sample size of only 53 patients. Our analysis of IAA would be expected to have increased power to detect any effect of INS VNTR because it is based on 491 patients and takes into account the age at clinical onset and other confounding variables.

Finally, that we did not observe associations between CTLA-4 and any of the immune markers is consistent with the results of a previous study in Belgian patients (48) but not the recent finding that CTLA-4 is associated with ICA512/IA-2A in Japanese patients (49). However, the Japanese patients had an increased prevalence of autoimmune thyroid disease compared with white patients, and CTLA-4 has been shown to be associated with autoimmune thyroid disease in several ethnic populations (50,51).

In conclusion, the present analysis of HLA, INS VNTR, and CTLA-4 gene polymorphisms in relation to IAA, GADA, ICA512/IA-2A, and ICA in 0- to 34-year-old Swedish incident patients with type 1 diabetes suggests that specific associations between genetic factors and autoantibodies may affect age-dependent risks for type 1 diabetes. First, GADA were less affected by age at clinical onset in patients than the other autoantibody markers. Patients with two HLA-DQ haplotypes had higher odds of GADA irrespective of age, whereas patients with no or one HLA-DQ2 haplotype had reduced odds of GADA in children. Female subjects had a threefold increased odds of GADA relative to male subjects. Second, the negative association between IAA and age at clinical onset was independent of the observed increased odds of IAA in patients with an increasing number of HLA-DQ8 haplotypes and of the observed increased odds of IAA in patients with an increasing number of class I alleles of the INS VNTR. Third, ICA512/IA-2A were also negatively associated with age at clinical onset. This age effect was independent of the observed increased odds of ICA512/IA-2A in patients with an increasing number of DQ8 haplotypes and of the observed increased odds of ICA512/IA-2A in patients with a decreasing number of DQ2 haplotypes. The negative association between ICA512/IA-2A and DQ2 is adjusted for the effects of confounding variables such as the number of HLA-DQ8 haplotypes, the age at onset, and sex and therefore cannot be attributed to exclusion of DQ8. Fourth, ICAs, whose reaction is explained by an immune response to multiple autoantigens, were also negatively associated with age at clinical onset in patients. This age effect was independent of the observed increased odds of ICA in patients with an increasing number of DQ8 haplotypes and of the observed increased odds of ICA in female patients. Finally, CTLA-4 was not associated with any of the autoantibody markers and may therefore confer risk for type 1 diabetes by a mechanism that is independent of the development of autoantibody markers. The present data underscore the importance of taking age and genetic factors into account when evaluating healthy subjects for type 1 diabetes risk.

ACKNOWLEDGMENTS
This work was supported by the Swedish Medical Research Council, the National Institutes of Health, the Juvenile Diabetes Foundation International, the Novo Nordisk Fund, the Swedish Diabetes Association, and Petrus and Agusta Hedlunds Stiftelse.

We are indebted to J. LaGasse, S. McGrew, S. Kaliappan, and C. Törn for excellent technical assistance.

The following authors are from the Diabetes Incidence Study in Sweden Study (DISS) Group: Hans Aruqvist, Department of Internal Medicine, University of Linköping, Linköping; Elisabeth Björck, Department of Medicine, University Hospital, Uppsala; Jan Eriksson, Department of Medicine, University of Umeå, Umeå; Lena Marström, Department of Epidemiology and Public Health, University of Umeå, Umeå; Lars Olof Ohlson, Sahlgrenska Hospital, University of Göteborg, Göteborg; Bengt Scherstén, Department of Community Health Sciences, Dahlby, Uni-
References


8. Vandewalle CL, Decraene T, Schutt FC, De-Leeuw JH, Pipeleers DG, Gorus FK: Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1*0301-DQB1*0202 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years. The Belgian Diabetes Registry. Diabetologia 36:1155–1162, 1993


31. Rabin DU, Pleasic SM, Palmer-Crocker R, Shapiro JA: Cloning and


